WRIGHT MEDICAL PUBLIC STATEMENT ON COVID-19
The health and safety of our employees, customers and communities is our priority. We have an active COVID-19 task force that is assessing any potential impact to our business. We are currently operating normally, and we have enacted several measures to protect the health and safety of our employees and to protect the continuity of supply to our customers. We will continue to vigilantly monitor the situation and implement additional actions as needed.
This is an unprecedented time for everyone, and the situation is changing daily. We are committed to maintaining our business operations and communicating with our customers if their service or products from Wright are impacted by the COVID-19 situation. We will keep you updated as events warrant.
Given that this is a rapidly evolving topic, Wright employees, customers and stakeholders should regularly monitor the Centers for Disease Control and Prevention website and similar websites for local authorities for any updated guidance as the situation evolves.
Thank you for your continued trust in Wright.
Wrightについて
Wright Medical Group N.V.は四肢とバイオ医薬品に特化し、グローバルに事業を展開する医療機器の会社です。私たちはイノベーティブで付加価値の高いソリューションをご提供することにより、世界中の患者さんの生活の質の向上を目指します。整形外科の分野で最も急成長を遂げる3つの分野である、上肢（肩、肘、手首、手）、下肢（足、足首）の外科的ソリューション、およびバイオ医薬品市場において、当社はその第一人者と認識されています。
医師を検索する
投資家情報
Data provided by Nasdaq. Minimum 15 minutes delayed.
- On June 8th, CMS published an update to the reimbursement calculation used to determine the transitional pass-through payment for the device category applicable to AUGMENT® Regenerative Solutions, which was originally implemented on 2020年1月1日.
- Based on this update, when hindfoot and ankle fusions are performed in the outpatient setting (hospital outpatient and ASC), the facility will be paid for AUGMENT® separate from the payment for the ankle fusion procedure without offset.
- This change is made retroactive to 2020年1月1日; claims that have been paid prior to June 8th will be adjusted retroactively to reflect the proper payment.
- This applies to beneficiaries enrolled in Medicare Part B under the traditional Medicare program (not Medicare Advantage beneficiaries or Commercially Insured patients).
- The pass-through payment will remain in place until Dec 31, 2022. By that time, CMS will have incorporated the cost data collected during the pass-through period (specifically the prior two years) to set the reimbursement rate for the applicable hindfoot and ankle fusion procedures for 2023 (and beyond).
*For additional AUGMENT® Reimbursement Support Tools and Information, visit japanese.wright.com/Reimbursement or contact us at [email protected].
To view the relevant information in the "July 2020 Update of the Hospital Outpatient Prospective Payment System (OPPS)" see bottom of pg. 16 through pg. 17 of the document via this link: https://www.cms.gov/files/document/mm11814.pdf.
